An Amazing Experience in Nepal
By Heather Brown, MD I had an amazing opportunity to spend a month working in the ED at Scheer Memorial Hospital in Banepa, Nepal, during my second year of residency. Scheer is a missionary hospital 30 kilometers outside Kathmandu with a six-bed emergency room open 24 hours a day. The ED was staffed with a mix of seasoned western physicians and young Nepali house staff who were mostly recent medical school graduates. There were plenty of chances to make a serious impact, and I was ready to do just that! Arriving in Nepal I’ve been passionate about international medicine since I was in college, and I couldn’t wait to work in such remote part of the world. I arrived ready for adventure after a 16-hour flight, and Kathmandu did not disappoint. The airport was absolute chaos. I was immediately surrounded by cab drivers trying to overcharge me and vendors selling everything from water to snake oil. I was finally able to find a police officer who directed me to an honest cab driver who drove me to Banepa. We wove through dusty city streets with no lanes and up winding mountain roads next to crowded buses and swerving cyclists. I was sure that I was going to die in the back of that cab, but I somehow arrived at the hospital in one piece. Dr. Brown in Nepal. The Emergency Room The patients at Scheer’s ED were not all that different from the patients I was used to in Columbia except the typical gastroenteritis patient in Nepal...
Authors: Rombauts A, Abelenda-Alonso G, Cuervo G, Gudiol C, Carratalà J Abstract INTRODUCTION: Despite adequate antibiotic coverage, community-acquired pneumonia (CAP) remains a leading cause of hospitalization and mortality worldwide. It induces both a local pulmonary and a systemic inflammatory response, particularly significant in severe cases. The intensity of the dysregulated host response varies from patient to patient and has a negative impact on survival and other outcomes. AREAS COVERED: This comprehensive review summarizes the pathophysiological aspects of the inflammatory response in CAP, brie...
CONCLUSIONS: Xyloglucan/gelose plus ORS was effective and safe in treating acute diarrhea in children. PMID: 33028102 [PubMed - as supplied by publisher]
CONCLUSIONS: Immunohistochemistry seems to be a promising option not only in clinical recognition, but also in the selection and monitoring of treatment effects. However, these methods have not yet recommended for routine clinical use. PMID: 33032462 [PubMed - as supplied by publisher]
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): Mario Gennaro Mazza, Rebecca De Lorenzo, Caterina Conte, Sara Poletti, Benedetta Vai, Irene Bollettini, Elisa Maria Teresa Melloni, Roberto Furlan, Fabio Ciceri, Patrizia Rovere-Querini, COVID-19 BioB Outpatient Clinic Study group, Francesco Benedetti
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): Xiaoqin Liu, Trine Munk-Olsen, Clara Albiñana, Bjarni J. Vilhjálmsson, Emil M. Pedersen, Vivi Schlünssen, Marie Bækvad-Hansen, Jonas Bybjerg-Grauholm, Merete Nordentoft, Anders D. Børglum, Thomas Werge, David M. Hougaard, Preben B. Mortensen, Esben Agerbo
Publication date: October 2020Source: Brain, Behavior, and Immunity, Volume 89Author(s): Fernando Lopes, Fernando A. Vicentini, Nina L. Cluny, Alexander J. Mathews, Benjamin H. Lee, Wagdi A. Almishri, Lateece Griffin, William Gonçalves, Vanessa Pinho, Derek M. McKay, Simon A. Hirota, Mark G. Swain, Quentin J. Pittman, Keith A. Sharkey
CONCLUSIONS: Individually customized, multicomponent exercise programs lead to improved levels of cognitive function, depression, and quality of life, especially among those who are more frail. PMID: 33029968 [PubMed]
CONCLUSIONS: Paramagnetic rims might be a characteristic MRI finding for MS, and therefore they have potential as an imaging marker for differentially diagnosing MS from NMOSD using 3-T MRI. PMID: 33029961 [PubMed]
Authors: Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K Abstract BACKGROUND: Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. AIM: To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients (≥ 75-years-old) compared to nonelderly patients, we conducted a post-marketing prospective cohort study. METHODS: We treated 265 patients with ge...
More News: Ativan | Blogging | Child Development | Children | Depression | Emergency Medicine | Gastroenteritis | Gastroenterology | Graduation | Health | Hospitals | International Medicine & Public Health | Lorazepam | Men | Nepal Health | PET Scan | Pneumonia | Poisoning | Postnatal Depression | Psychiatry | Residencies | Students | Suicide | Tuberculosis | Typhoid | Universities & Medical Training